Biocon Biologics, Serum Institute Life Sciences to expand tie-up for R & D, new vaccines

On Thursday, Biocon had said it will offer around 15 per cent stake to Serum Institute Life Sciences at a post-money valuation of about Rs36000 crore ($4.9 billion) where 15% will be valued at about Rs5100 crore. Post transaction, Biocon Ltd will hold 74.89% stake in Biocon Biologics. Serum Institute Life Sciences (SILS) is a subsidiary of Serum Institute of India (SII).
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news